OS THERAPIES INCORPORATED Net Fee Amt
OS THERAPIES INCORPORATED (OSTX) had Net Fee Amt of $1.18 thousand as of 2026-09-15, per its S-8 filed 2026-09-21.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-21
- 2026-09-15: Net Fee Amt $1.18K.
- 2026-09-10: Net Fee Amt $1.35K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-15 | $1.18K S-8 · filed 2026-09-21 |
| 2026-09-10 | $1.35K 424B7 · filed 2026-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |